CenterBook Partners’s RAPT Therapeutics RAPT Stock Holding History

CenterBook Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,931	Closed	-$781K	–	474
2023 Q4	$781K	Buy	+3,931	New	+$487K	0.1%	279

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CenterBook Partners's RAPT Position: Q1 2024 in Review

CenterBook Partners sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 3,931 shares — an estimated $781K sold.

CenterBook Partners first reported a position in RAPT in Q4 2023 and held it in 1 quarter. The position peaked at $781K in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

CenterBook Partners reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
CenterBook Partners sold 3,931 RAPT Therapeutics shares in Q1 2024, an estimated $781K.
CenterBook Partners first reported a position in RAPT Therapeutics in Q4 2023 and held it in 1 quarter.
CenterBook Partners's RAPT Therapeutics position peaked at $781K in Q4 2023.
121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on CenterBook Partners's 13F filing for Q1 2024, filed 10 May 2024.